FibroGen Terminates Material Definitive Agreement
Ticker: KYNB · Form: 8-K · Filed: Oct 3, 2024 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $10 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, termination
Related Tickers: FGEN
TL;DR
FibroGen just terminated a big deal, could be good or bad.
AI Summary
FibroGen, Inc. reported on September 27, 2024, the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the agreement, but it marks a significant event for the company.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding the company's business relationships and financial projections.
Key Players & Entities
- FibroGen, Inc. (company) — Registrant
- September 27, 2024 (date) — Date of earliest event reported
- 350 Bay Street Suite 100 #6009 (address) — Principal Executive Offices
- San Francisco, California (location) — Principal Executive Offices
- 94133 (zip_code) — Principal Executive Offices
- 415 978-1200 (phone_number) — Registrant's Telephone Number
FAQ
What was the material definitive agreement that was terminated?
The filing does not specify the details of the material definitive agreement that was terminated.
Who was the counterparty to the terminated agreement?
The filing does not disclose the name of the counterparty to the terminated agreement.
What is the effective date of the termination?
The earliest event reported is September 27, 2024, which is the date of the report and the date of the change.
What are the potential financial implications of this termination for FibroGen?
The filing does not provide specific details on the financial implications of the termination.
Does this termination affect any ongoing clinical trials or product development?
The filing does not contain information regarding the impact of the termination on clinical trials or product development.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 13.8 · Accepted 2024-10-03 16:05:23
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se
- $10 million — Agreement, FibroGen and ARE agreed on a $10 million settlement amount, consisting of (1) a
Filing Documents
- fgen-20240927.htm (8-K) — 38KB
- 0000950170-24-112331.txt ( ) — 179KB
- fgen-20240927.xsd (EX-101.SCH) — 43KB
- fgen-20240927_htm.xml (XML) — 6KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. As part of the continuing efforts of FibroGen, Inc. ("FibroGen") to reduce operating expenses and preserve cash, on September 27, 2024, FibroGen entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises ("Lease Termination Agreement") with its landlord, ARE-San Francisco No.43 Owner, LLC ("ARE") related to the premises located at 409 Illinois Street, San Francisco, California 94158. The Lease Termination Agreement modifies the Lease Agreement dated as of September 22, 2006, as subsequently amended (the "Lease") and accelerates the expiration date of the term of the Lease to December 31, 2024. In consideration of the Lease Termination Agreement, FibroGen and ARE agreed on a $10 million settlement amount, consisting of (1) a one-time cash payment by FibroGen for past rent, FibroGen's share of operating costs, taxes, insurance, utilities, and other costs, and a Lease modification payment, and (2) a security deposit, in the form of a letter of credit. As of execution of this Lease Termination Agreement, FibroGen shall not be responsible for the payment of any further rent payments or operating costs, taxes, insurance, utilities, or any other scheduled monthly payments due under the Lease to ARE.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FIBROGEN, INC. Date: October 3, 2024 By: /s/ Michael Lowenstein Michael Lowenstein Chief Legal Officer